First, some happy personal news about my health. I had a six-week follow-up with the shoulder surgeon today, and I no longer have to wear a sling for my surgically-repaired shoulder. I feel a little more like myself. I have many months of physical therapy ahead of me, but now I can drive and sleep in my own bed and give my wife a hug with both arms. Pretty nice.
As I said in my last post, the abstracts for the ASH meeting were a little bit late, but I did finally get a chance to read them, though it was a quick read. There were some obvious themes. Lots on CAR-T and bispecifics. A good amount of research on biomarkers. Some “real world” studies that look at how treatments are working after they have been approved.
But one thing that really stood out most was one single word: Cure.
It would have been impossible to see this word in an abstract about Follicular Lymphoma in the past, even a year ago. But a few researchers dared to include it this year.
Of course, the mere mention of the word “cure” was made possible by research that was published last spring. Researchers proposed that about 40% of FL patients who had received immunochemotherapy were cured by a 15 year follow up. This caused a great deal of discussion in the FL community. Those of us who were diagnosed before March 2026 were told that Follicular Lymphoma is incurable. Maybe those of you who have been diagnosed in the last six months or so have been told that the disease might be curable. But the idea of a cure has always been something that many of us -- patients and doctors -- did not dare say.
The folks at the Follicular Lymphoma Foundation did an interview with one of the researchers from tat study and wrote about the research. They asked me for my thoughts, which were included in the article. One of my main thoughts was that we have been told for so long that FL is not curable that it's going to take some courage for us -- patients and doctors -- to believe that it might be.
And now, here we are, with at least 3 presentations at ASH in 2026 that explore the idea that Follicular Lymphoma might be curable.
The first one is abstract #3551 Follicular lymphoma (FL) as a curable disease: Late lymphoma-related event rates in immunochemotherapy treated follicular lymphoma are similar to traditionally curable lymphomas (DLBCL and cHL). The researchers for this study looked at their own database, and found that after 10 years, FL patients showed a decrease in the rate of progression of disease and in how frequently patients needed to be treated again. To better understand whether FL was curable, they compared those instances of progression and need for treatment to two other Lymphomas that are considered curable -- Diffuse Large B Cell Lymphoma and classical Hodgkin's Lymphoma. They found that FL patients whose disease did not progress for 10 years had a similar disease path as patients with DLBCL and Hodgkin's Lymphoma after five years -- the amount of time that patients with those diseases are considered cured. The researchers aren't necessarily suggesting that those FL patients were cured, but they do believe that this supports the idea that FL might be curable, since their disease is behaving very similarly to patients with curable diseases.
Another presentation also looks at the idea of curability in FL. In abstract #3578 Using event-free survival at 24 months and baseline FLIPI24 to identify cure in follicular lymphoma, researchers used FLIPI24, a prognostic model, to determine which patients might be curable have curable disease. (I'm not going to get into FLIPI24, but you can read more about it here on your own. Just remember that prognostic models like this predict risk. But it doesn't say anything about you as an individual, and it cannot predict your own individual disease path, good or bad.) The researchers looked at patients who had achieved EFS24, that is, who had received immunochemotherapy and had then gone for 24 months without their disease progressing. They wanted to see if EFS24 patients with a low FLIPI24 score would have an overall survival (as a group) that was roughly the same as the general population.
They found that EFS24 patients with lower FLIPI24 scores at very low lymphoma rated mortality and had an overall survival that was comparable to the general population. Patients with higher risk FLIPI24 scores had a slightly lower overall survival than the general population, though lymphoma-related deaths were uncommon. They believe that FLIPI24 scores may predict which EFS24 patients will have a survival that is in line with the general population. In other words, it might predict that a certain group of patients is functionally cured.
On the other hand, other researchers found that FL prognostic scores cannot identify which patients might be cured. In abstract #1735 Current prognostic indices are unable to identify cured populations with FL: Comparison of three follicular lymphoma prognostic scoring systems in SWOG S0016 with long-term follow-up, researchers tested whether or not three different prognostic scores could possibly predict cure. They tested FLIPI, m7-FLIPI, and FL24Cx to determine how well they could predict success. Again, I won’t get into how these prognostic tools work. They have been shown over the years to have limited use in predicting any single individual patient’s outcomes. With that in mind, the results here are not really a surprise. The researchers found that these tools are good at identifying high risk patients (since they ask questions that determine if a patient is high risk), but they aren’t good at identifying whether or not a patient is cured. That’s just not what they were designed to do.
But the more important point is this – doctors and researchers (and probably patients) are daring to use the “c” word. The idea that FL might be curable, even for a small portion of us, is something that most people in the community would not talk about in the past. And now it’s being talked about.
I’d love to know how many conversations at the ASH meeting are centered on this. The ASCO conference happened just a couple of months after the “curable” research was published, so there wasn’t time to do any kind of research that was related to it. But now there has been time. And we’re starting to see some of it.
It’s going to be exciting to read and watch the commentaries after the meeting is over, to see if curability is a big topic. I’ll certainly pass that along when I see it.
In the meantime, I’ll go back through those FL abstracts and share a few more that I find interesting. Stay tuned.